HCT Consolidation Improves Survival in Younger MCL Patients

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/nivolumab combination regimen, 3 had remission beyond 2 years.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Nathalie Soler, MD;Kelly Paz Amador, MD;Alexandra Perez, MD;Camila Solis, MD;Alexander Reyes, MD;Jorge Garcia, MD;Maria Paula Gonzalez Zambrano, MD;Edgar Fabián Manrique Hernández, MD, MSc, PhD (c)

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

Acalabrutinib Combo Receives EU Approval for Mantle Cell Lymphoma

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Support for the decision follows a positive opinion from the Committee for Medicinal Products for Human Use based on the phase 3 ECHO trial results.

FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

Support for the decision follows a positive opinion from the Committee for Medicinal Products for Human Use based on the phase 3 ECHO trial results.

Tim Cortese

Ibrutinib/Nivolumab Shows Clinical Activity in R/R CNS Lymphoma

The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.

Related Content

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/nivolumab combination regimen, 3 had remission beyond 2 years.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Nathalie Soler, MD;Kelly Paz Amador, MD;Alexandra Perez, MD;Camila Solis, MD;Alexander Reyes, MD;Jorge Garcia, MD;Maria Paula Gonzalez Zambrano, MD;Edgar Fabián Manrique Hernández, MD, MSc, PhD (c)

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

Acalabrutinib Combo Receives EU Approval for Mantle Cell Lymphoma

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

Support for the decision follows a positive opinion from the Committee for Medicinal Products for Human Use based on the phase 3 ECHO trial results.

Tim Cortese